详情页 - 四川省肿瘤医院知识库

当前位置：首页 > 详情页

Durvalumab Plus Anlotinib Versus Durvalumab as Maintenance Treatment in ES-SCLC (DURABLE): A Randomized, Phase 2 Trial

文献详情

资源类型：

WOS体系：

收录情况： ◇ SCIE

作者：

机构： [1]Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Shanghai, Peoples R China [2]Shanghai Jiao Tong Univ, Sch Med, Shanghai Chest Hosp, Dept Resp & Crit Care Med 1, Shanghai, Peoples R China [3]Shanghai Jiao Tong Univ, Sch Med, Shanghai Chest Hosp, Dept Resp & Crit Care Med, Shanghai, Peoples R China [4]Nanchang Univ, Affiliated Hosp 1, Dept Resp Med 5, Nanchang, Jiangxi, Peoples R China [5]Anhui Prov Canc Hosp, Dept Resp & Crit Care Med 3, Hefei, Anhui, Peoples R China [6]Shanxi Hosp, Affiliated Canc Hosp, Shanxi Prov Canc Hosp, Dept Med Oncol 4, Taiyuan, Peoples R China [7]Sichuan Canc Hosp, Dept Thorac Oncol, Chengdu, Peoples R China

出处：

ISSN：

关键词： extensive-stage small-cell lung cancer maintenance treatment anti-vascular agent

语种：

WOS：

中科院(CAS)分区：

出版当年[2024]版：

无

最新[2023]版：

大类 | 1 区

医学

小类 | 1 区肿瘤学 1 区呼吸系统

JCR分区：

出版当年[2024]版：

无

最新[2023]版：

Q1 ONCOLOGY Q1 RESPIRATORY SYSTEM

影响因子： 21.1 最新[2023版] 16.5 最新五年平均 21.1 出版当年[2023版] 0 出版当年五年平均 21.1 出版前一年[2023版]

第一作者：

第一作者机构： [1]Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Shanghai, Peoples R China

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]Study of Platinum Plus Etoposide With or Without BGB-A317 in Participants With Untreated Extensive-Stage Small Cell Lung Cancer [2]Myeloprotection with Trilaciclib in Chinese Patients with Extensive-Stage Small Cell Lung Cancer Receiving Standard Chemotherapy (TRACES) [3]First-line atezolizumab/durvalumab plus platinum-etoposide combined with radiotherapy in extensive-stage small-cell lung cancer [4]Assessing treatment outcomes of chemoimmunotherapy in extensive-stage small cell lung cancer: an integrated clinical and radiomics approach [5]Brief report: Ivonescimab combined with etoposide plus carboplatin as first-line treatment for extensive-stage small-cell lung cancer: results of a phase Ib clinical trial [6]Apatinib and Etoposide as the Maintenance Therapy in Extensive-stage Small Cell Lung Cancer After First-line Chemotherapy [7]Comparable Local Controls after Twice-Daily and Once-Daily Chest Radiotherapy in Extensive Stage Small Cell Lung Cancer [8]Pembrolizumab/Vibostolimab (MK-7684A) or Atezolizumab in Combination With Chemotherapy in First Line Treatment of Extensive-Stage Small Cell Lung Cancer (MK-7684A-008, KEYVIBE-008) [9]Toripalimab Plus Chemotherapy as a First-Line Therapy for Extensive-Stage Small Cell Lung Cancer: The Phase 3 EXTENTORCH Randomized Clinical Trial [10]Efficacy and safety of apatinib as second or later-line therapy in extensive-stage small cell lung cancer: a prospective, exploratory, single-arm, multi-center clinical trial.